 ROCKVILLE, Md., June 29, 2021 PRNewswire -- Synthetic Biologics, Inc. NYSE American: SYN, a diversified clinical-stage company leveraging the microbiome to develop therapeutics designed to prevent and treat gastrointestinal GI diseases in areas of high unmet need, today announced that patient dosing and observation has been completed in its Phase 1, open label, single-ascending dose SAD clinical trial of SYN-020 intestinal alkaline phosphatase IAP. 